In 2023, the Center for Drug Evaluation and Research (CDER) of the US Food and Drug Administration (FDA) approved 55 novel drugs, 4 related to gastroenterology and hepatology.

In 2022, the new drug approvals included treatments for Helicobacter pylori infection, T2DM blood sugar control in addition to diet and exercise, FGFR2-aberrant intrahepatic cholangiocarcinoma and unresectable hepatocellular carcinoma.